Adaptimmune Therapeutics plc has announced a definitive agreement to sell its TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to US WorldMeds. The sale is expected to be completed by the end of the week. As part of the transaction, US employees involved in the development and commercialization of these therapies will be offered employment with US WorldMeds to ensure continuity. Adaptimmune plans to restructure to support US WorldMeds in the ongoing development of these therapies, while focusing on maximizing value from its remaining assets, including its PRAME and CD70 directed T-cell therapies. The transaction will be financed by debt financing led by Oaktree Capital Management, L.P., with participation from Athyrium Capital Management, LP. US WorldMeds' CEO, Breck Jones, emphasized the company's commitment to advancing these therapies, while Adrian Rawcliffe, CEO of Adaptimmune, highlighted the strategic importance of this transaction for the company and its stakeholders.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.